Dynapenia and Sarcopenia as Risk Factors for Mortality in Interstitial Lung Disease.

IF 6.3 2区 医学 Q1 RESPIRATORY SYSTEM Respirology Pub Date : 2025-05-01 Epub Date: 2025-02-04 DOI:10.1111/resp.14892
Alan Aldair Ibarra-Fernández, Robinson Robles-Hernández, Arturo Orea-Tejeda, Dulce González-Islas, Angelia Jiménez-Valentín, Rocío Sánchez-Santillán, Laura Patricia Arcos-Pacheco, Emilio Gutiérrez-Luna, Andrea Zurita-Sandoval, Tomas Peña-Espinosa, Rosaura Gutiérrez-Vargas, Laura Flores-Cisneros
{"title":"Dynapenia and Sarcopenia as Risk Factors for Mortality in Interstitial Lung Disease.","authors":"Alan Aldair Ibarra-Fernández, Robinson Robles-Hernández, Arturo Orea-Tejeda, Dulce González-Islas, Angelia Jiménez-Valentín, Rocío Sánchez-Santillán, Laura Patricia Arcos-Pacheco, Emilio Gutiérrez-Luna, Andrea Zurita-Sandoval, Tomas Peña-Espinosa, Rosaura Gutiérrez-Vargas, Laura Flores-Cisneros","doi":"10.1111/resp.14892","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Fibrotic interstitial lung disease (ILD) is associated with high morbidity and mortality. Patients often exhibit impaired nutritional status and alterations in body composition, such as dynapenia and sarcopenia, which correlate with poor pulmonary function, reduced exercise tolerance and diminished quality of life. However, the impact of dynapenia and sarcopenia on prognosis has not been examined extensively in ILD patients. We assessed the impact of dynapenia and sarcopenia as risk factors for mortality and their prevalence in ILD.</p><p><strong>Methods: </strong>Prospective cohort study. ILD was classified into idiopathic pulmonary fibrosis (IPF), connective tissue disease-related ILD (CTD-ILD) and chronic hypersensitivity pneumonitis (CHP). Patients over 18 years old with a confirmed diagnosis of ILD were included, while those with diagnoses of cancer, human immunodeficiency virus and neurological disease were excluded. Dynapenia and sarcopenia were determined according to EWGSOP2 criteria.</p><p><strong>Results: </strong>Ninety-eight ILD patients were included; 33.66% had IPF, 47.96% had CTD-ILD, and 18.37% had CHP. The mean age was 63.89 ± 12.02 years; 37.76% were male. The risk factors associated with mortality included dynapenia (HR: 2.04, 95% CI: 1.10-3.77, p = 0.022), sarcopenia (HR: 1.88, 95% CI; 1.00-3.33, p = 0.049) and exercise tolerance (HR: 0.99, 95% CI; 0.99-0.99, p = 0.023), adjusted for confounding variables. The prevalence of dynapenia was 45% in ILD; 51% in IPF, 35% in CTD-ILD and 61% in CHP. The prevalence of sarcopenia was 29%; both IPF (39%) and CHP (50%) had a higher prevalence of sarcopenia than CTD-ILD (14%).</p><p><strong>Conclusion: </strong>Sarcopenia and dynapenia are independent risk factors for mortality in ILD.</p>","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":"424-434"},"PeriodicalIF":6.3000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12060744/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respirology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/resp.14892","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: Fibrotic interstitial lung disease (ILD) is associated with high morbidity and mortality. Patients often exhibit impaired nutritional status and alterations in body composition, such as dynapenia and sarcopenia, which correlate with poor pulmonary function, reduced exercise tolerance and diminished quality of life. However, the impact of dynapenia and sarcopenia on prognosis has not been examined extensively in ILD patients. We assessed the impact of dynapenia and sarcopenia as risk factors for mortality and their prevalence in ILD.

Methods: Prospective cohort study. ILD was classified into idiopathic pulmonary fibrosis (IPF), connective tissue disease-related ILD (CTD-ILD) and chronic hypersensitivity pneumonitis (CHP). Patients over 18 years old with a confirmed diagnosis of ILD were included, while those with diagnoses of cancer, human immunodeficiency virus and neurological disease were excluded. Dynapenia and sarcopenia were determined according to EWGSOP2 criteria.

Results: Ninety-eight ILD patients were included; 33.66% had IPF, 47.96% had CTD-ILD, and 18.37% had CHP. The mean age was 63.89 ± 12.02 years; 37.76% were male. The risk factors associated with mortality included dynapenia (HR: 2.04, 95% CI: 1.10-3.77, p = 0.022), sarcopenia (HR: 1.88, 95% CI; 1.00-3.33, p = 0.049) and exercise tolerance (HR: 0.99, 95% CI; 0.99-0.99, p = 0.023), adjusted for confounding variables. The prevalence of dynapenia was 45% in ILD; 51% in IPF, 35% in CTD-ILD and 61% in CHP. The prevalence of sarcopenia was 29%; both IPF (39%) and CHP (50%) had a higher prevalence of sarcopenia than CTD-ILD (14%).

Conclusion: Sarcopenia and dynapenia are independent risk factors for mortality in ILD.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
作为间质性肺病死亡率风险因素的动力性减少症和肌少症
背景和目的:纤维化间质性肺疾病(ILD)具有较高的发病率和死亡率。患者通常表现为营养状况受损和身体组成改变,如动力不足和肌肉减少症,这与肺功能不良、运动耐受性降低和生活质量下降有关。然而,在ILD患者中,动力减少和肌肉减少对预后的影响尚未得到广泛的研究。我们评估了动力不足和肌肉减少作为死亡率和ILD患病率的危险因素的影响。方法:前瞻性队列研究。ILD分为特发性肺纤维化(IPF)、结缔组织病相关ILD (CTD-ILD)和慢性超敏性肺炎(CHP)。18岁以上确诊为ILD的患者被纳入研究,而那些诊断为癌症、人类免疫缺陷病毒和神经系统疾病的患者被排除在外。根据EWGSOP2标准确定肌肉减少和动力减少。结果:纳入ILD患者98例;IPF占33.66%,CTD-ILD占47.96%,CHP占18.37%。平均年龄63.89±12.02岁;37.76%为男性。与死亡率相关的危险因素包括:动力不足(HR: 2.04, 95% CI: 1.10-3.77, p = 0.022)、肌肉减少(HR: 1.88, 95% CI;1.00-3.33, p = 0.049)和运动耐量(HR: 0.99, 95% CI;0.99-0.99, p = 0.023),校正了混杂变量。ILD患者动力不足的发生率为45%;IPF为51%,CTD-ILD为35%,CHP为61%。肌肉减少症患病率为29%;IPF(39%)和CHP(50%)的肌少症患病率均高于CTD-ILD(14%)。结论:肌少症和动力不足是ILD患者死亡的独立危险因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Respirology
Respirology 医学-呼吸系统
CiteScore
10.60
自引率
5.80%
发文量
225
审稿时长
1 months
期刊介绍: Respirology is a journal of international standing, publishing peer-reviewed articles of scientific excellence in clinical and clinically-relevant experimental respiratory biology and disease. Fields of research include immunology, intensive and critical care, epidemiology, cell and molecular biology, pathology, pharmacology, physiology, paediatric respiratory medicine, clinical trials, interventional pulmonology and thoracic surgery. The Journal aims to encourage the international exchange of results and publishes papers in the following categories: Original Articles, Editorials, Reviews, and Correspondences. Respirology is the preferred journal of the Thoracic Society of Australia and New Zealand, has been adopted as the preferred English journal of the Japanese Respiratory Society and the Taiwan Society of Pulmonary and Critical Care Medicine and is an official journal of the World Association for Bronchology and Interventional Pulmonology.
期刊最新文献
Likelihood of Usual Interstitial Pneumonia: A Novel Approach to Prognosis for Pulmonary Fibrosis. Effects of Air Pollution Exposure and the MUC5B rs35705950 Variant on Interstitial Lung Disease Risk in Patients With Rheumatoid Arthritis. Association Between Single Nucleotide Polymorphisms and Disease Susceptibility, Survival, and Acute Exacerbation in Idiopathic Pulmonary Fibrosis. Prediction of Pulmonary Ground-Glass Nodule Progression State on Initial Screening CT Using a Radiomics-Based Model. The Association Between Use of Inhaled Corticosteroids and Long-Acting Beta2-Agonists During Pregnancy and Adverse Fetal Outcomes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1